CN106173853B - Nutritional composition for reducing blood fat and application thereof - Google Patents
Nutritional composition for reducing blood fat and application thereof Download PDFInfo
- Publication number
- CN106173853B CN106173853B CN201610558034.1A CN201610558034A CN106173853B CN 106173853 B CN106173853 B CN 106173853B CN 201610558034 A CN201610558034 A CN 201610558034A CN 106173853 B CN106173853 B CN 106173853B
- Authority
- CN
- China
- Prior art keywords
- powder
- trachinotus ovatus
- peptide
- nutritional composition
- cooked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 39
- 239000008280 blood Substances 0.000 title claims abstract description 39
- 230000001603 reducing effect Effects 0.000 title claims abstract description 37
- 235000016709 nutrition Nutrition 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 91
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 55
- 241000719209 Trachinotus ovatus Species 0.000 claims abstract description 44
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 235000013339 cereals Nutrition 0.000 claims abstract description 16
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 13
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 13
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 13
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 12
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000005119 centrifugation Methods 0.000 claims abstract description 3
- 235000013402 health food Nutrition 0.000 claims abstract 2
- 235000013312 flour Nutrition 0.000 claims description 15
- 240000008042 Zea mays Species 0.000 claims description 11
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 11
- 235000005822 corn Nutrition 0.000 claims description 11
- 235000019545 cooked cereal Nutrition 0.000 claims description 10
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 10
- 150000002632 lipids Chemical class 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000004365 Protease Substances 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 235000019419 proteases Nutrition 0.000 claims description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims description 3
- 235000013372 meat Nutrition 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000003531 protein hydrolysate Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 108091005658 Basic proteases Proteins 0.000 claims description 2
- 241000371652 Curvularia clavata Species 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 108090000526 Papain Proteins 0.000 claims description 2
- 108090000284 Pepsin A Proteins 0.000 claims description 2
- 102000057297 Pepsin A Human genes 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 229940055729 papain Drugs 0.000 claims description 2
- 235000019834 papain Nutrition 0.000 claims description 2
- 229940111202 pepsin Drugs 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 235000014105 formulated food Nutrition 0.000 claims 1
- 239000003613 bile acid Substances 0.000 abstract description 12
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract description 5
- 235000012055 fruits and vegetables Nutrition 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract description 5
- 239000000084 colloidal system Substances 0.000 abstract description 4
- 230000002440 hepatic effect Effects 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 235000008476 powdered milk Nutrition 0.000 abstract description 2
- 230000033764 rhythmic process Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 28
- 230000000694 effects Effects 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 17
- 108010023302 HDL Cholesterol Proteins 0.000 description 14
- 235000012000 cholesterol Nutrition 0.000 description 13
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 241000276694 Carangidae Species 0.000 description 7
- 210000003608 fece Anatomy 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 229920001268 Cholestyramine Polymers 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940099352 cholate Drugs 0.000 description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000723298 Dicentrarchus labrax Species 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031200 bile acid secretion Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000011629 hyperlipidemia animal model Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention belongs to the field of production of nutritional foods, and particularly discloses a nutritional composition for reducing blood fat, which comprises the following components in percentage by mass: 40-60% of cured cereal powder and maltodextrin, 15-35% of trachinotus ovatus peptide powder and skimmed milk powder, 10-20% of fruit and vegetable powder and 2-5% of sodium carboxymethylcellulose; the trachinotus ovatus peptide powder is obtained by performing enzymolysis, centrifugation, ultrafiltration and drying on trachinotus ovatus. The cured grain powder and the fruit and vegetable powder provided by the invention are rich in dietary fiber, and the sodium carboxymethylcellulose can further enhance the colloidal system of the dietary fiber in the intestinal tract, and can be compounded with the trachinotus ovatus peptide powder, so that the hepatic and intestinal circulation of bile acid is obviously reduced, the discharge of the bile acid along with excrement is increased, and the purpose of reducing blood fat is achieved. The nutritional composition can be used as health food, formula food with special medical application and common food, and is suitable for sub-healthy people with hyperlipidemia, who are busy in work and have a short life rhythm.
Description
Technical Field
The invention belongs to the technical field of nutritional foods, and particularly relates to a nutritional composition for reducing blood fat and application thereof.
Background
Hyperlipidemia is a common cardiovascular disease caused by disorder of blood lipid metabolism, and its main symptoms include elevation of Total Cholesterol (TC), total Triacylglycerol (TG), low-density lipoprotein cholesterol (LDL-c), and lowering of high-density lipoprotein cholesterol (HDL-c) in serum. The occurrence of hyperlipidemia is closely related to personal daily work and rest, especially improper dietary habits, besides genetic factors. The excessive high content of blood fat can further cause blood viscosity to induce various cardiovascular diseases, and hypertension and diabetes are also complications of hyperlipidemia, thereby causing great harm to human health. Dysregulated blood lipids are considered to be the basis for primary and secondary prevention of cardiovascular disease, significantly reducing the risk of death from cardiovascular disease. The chemical hypolipidemic drugs used clinically at present have definite curative effects, but have large side effects and high recurrence rate.
At present, researches find that the food-derived active substances can achieve the aim of assisting in reducing blood fat by a method of promoting bile acid secretion and reducing bile acid absorption. The food therapy method is used for assisting in reducing blood fat, and is safe and harmless, so that the food therapy method is more and more popular among doctors and patients. The method is based on the fact that about 40-50% of cholesterol in the human body is metabolically decomposed by the synthesis of bile acids. When the components in the food can combine with the bile acid to take away and discharge more bile acid in the intestinal tract after the food is digested, more cholesterol in the blood can be promoted to synthesize the bile acid to maintain the normal digestion and absorption of lipid food, thereby reducing the content of cholesterol in the blood and the body.
According to the existing research reports, the functional components with the function of assisting in reducing blood fat in food mainly comprise dietary fibers, bioactive peptides, fatty acids, phytosterols, phenols, polysaccharides and the like.
Among them, bioactive peptides are one of the most popular fields of research in the current functional food industry. The peptides, especially some oligopeptides, have the function of regulating the physiological function of the human body and have important application prospect in the food for assisting to reduce blood fat. At present, the research and development of the hypolipidemic effect of bioactive peptides at home and abroad are mainly focused on bean protein peptides and glycoprotein peptides, and the research on the preparation of the hypolipidemic peptides from marine fish proteins is rarely reported at home and abroad.
Bioactive peptides of marine origin have more broadly distinct biological activities due to differences in their amino acid composition and sequence from that of terrestrial organisms. At present, research on the aspect of reducing blood fat peptide of marine organisms mainly focuses on mollusks such as jellyfish collagen peptide.
The effect of dietary fiber on human health is more and more concerned by the world, and the dietary fiber also has obvious effect on reducing blood fat. The dietary fiber has active groups and physical properties of a colloidal system, so that the dietary fiber can adsorb cholesterol and cholate in intestinal tracts, and the formed colloidal system can prevent bile acid and cholesterol from migrating and absorbing to intestinal mucosa, thereby achieving the purpose of reducing bile acid liver and intestine circulation.
The invention aims to obtain the nutrient product for reducing the hyperlipidemia by combining the means, so that the nutrient product is used for people with demands, and the remarkable effect of assisting in reducing the hyperlipidemia is achieved.
Disclosure of Invention
The invention aims to provide a nutritional composition for reducing blood fat according to the defects in the prior art.
The invention also aims to provide the application of the nutritional composition in preparing hyperlipidemia medicines, health-care foods, special medical application formula foods and common foods.
The purpose of the invention is realized by the following technical scheme:
the invention provides a nutritional composition for reducing blood fat, which comprises the following components in percentage by mass:
40-60% of cured cereal powder and maltodextrin,
15-35% of trachinotus ovatus peptide powder and skimmed milk powder,
10-20% of fruit and vegetable powder
2-5% of sodium carboxymethylcellulose;
the trachinotus ovatus peptide powder is obtained by carrying out enzymolysis on trachinotus ovatus, centrifuging, filtering and drying.
The invention prepares oval pompano into small molecule peptide powder, which is different from marine animal peptide disclosed in the prior art, for example, a patent of 'a tube feeding clinical nutriment with hypolipidemic effect and a preparation method thereof' (CN 103637212A) discloses that sea bass is used as a raw material to prepare a clinical nutriment preparation with the hypolipidemic effect, but compared with the patent, the invention has different raw materials (ocean oval pompano) and different food populations (sub-healthy common population which can be eaten independently) and most importantly has different action mechanisms, namely the invention utilizes oval pompano peptide to be combined with other components to play a role of reducing blood lipid by blocking liver and intestine circulation of bile acid, and the action mechanism of the patent (CN 103637212A) mainly plays a role of reducing blood lipid by regulating an enzyme system in vivo.
Preferably, the content of the cured cereal powder and the maltodextrin in the cured cereal powder is 9-95%, and the content of the oval pompano peptide powder in the oval pompano peptide powder and the skimmed milk powder is 1-95%.
More preferably, the content of the cured cereal powder and maltodextrin in the cured cereal powder is 60-91%, and the content of the oval pompano peptide powder in the oval pompano peptide powder and the skimmed milk powder is 40-80%.
More preferably, the weight ratio of the cooked cereal powder to the trachinotus ovatus peptide powder is (2.0-3.5): 1.
in the invention, the dietary fiber and the trachinotus ovatus peptide powder have synergistic effect, and are combined with cholate in intestinal tracts to slow the reabsorption of the cholate, thereby jointly playing a role in reducing blood fat.
Preferably, the proportion of the protein hydrolysate of the trachinotus ovatus peptide powder with the relative molecular weight of less than 3000Da is more than 95%.
Preferably, the cooked cereal flour is comprised of one or more of cooked oat flour, cooked corn flour, cooked rice flour, cooked black rice flour.
More preferably, the cooked cereal flour comprises cooked oat flour and cooked corn flour in a weight ratio of cooked oat flour to cooked corn flour of 5: 2.
preferably, the preparation of the trachinotus ovatus peptide powder comprises the following steps:
s1, adding 1 time of water into trachinotus ovatus meat and smashing;
s2, adding 2000-6000U/g protease into the crushed trachinotus ovatus in the S1, hydrolyzing for 2-6 hours, inactivating enzyme at 95 ℃, cooling to 4-10 ℃, and centrifuging;
s3, taking the supernatant obtained after centrifugation in the S2, filtering the supernatant through a 10,000-3,000 MWCO ultrafiltration membrane, and drying the filtrate to obtain the trachinotus ovatus peptide powder.
Preferably, in S2, the protease is one or more of pepsin, trypsin, alkaline protease and papain.
Preferably, the separation factor F in the centrifuger≥ 800。
The cured grain powder and the fruit and vegetable powder provided by the invention are rich in dietary fiber, and the sodium carboxymethylcellulose can further enhance the colloidal system of the dietary fiber in the intestinal tract, and can be compounded with the trachinotus ovatus peptide powder to generate a synergistic interaction effect, so that the hepatic and intestinal circulation of bile acid is obviously reduced, the discharge of the bile acid along with excrement is increased, and the purpose of reducing blood fat is achieved. And after being compounded, the components of the invention have synergistic effect obviously stronger than the independent effect of the components.
Compared with the prior art, the invention has the following advantages and beneficial effects:
the nutritional food prepared from the nutritional composition provided by the invention can reduce the content of Total Cholesterol (TC), total Triacylglycerol (TG) and low-density lipoprotein cholesterol (LDL-c) in serum, and remarkably improve the content of high-density lipoprotein cholesterol (HDL-c) and total cholesterol (FTC) in excrement, has a remarkable blood fat reducing effect, has a great application prospect when being used for preparing hyperlipidemia medicines, health-care foods, special medical purpose formula foods and common foods, and is particularly suitable for hyperlipidemia sub-health people with busy work and short life rhythm.
Drawings
FIG. 1 is a schematic diagram of the molecular weight distribution of Trachinotus ovatus peptide powder in example 1.
FIG. 2 is a schematic diagram of the molecular weight distribution of Trachinotus ovatus peptide powder in example 10.
FIG. 3 is a graph of the effect of gavage samples on serum TC levels in rats.
FIG. 4 is a graph of the effect of gavage samples on rat serum TG levels.
FIG. 5 is a graph of the effect of gavage samples on rat serum LDL-c levels.
FIG. 6 is a graph of the effect of gavage samples on rat serum HDL-c levels.
FIG. 7 is a graph of the effect of gavage samples on total cholesterol levels (FTC) in rat feces.
Detailed Description
The present invention will be further described with reference to the following specific examples and drawings, which are not intended to limit the invention in any manner. Reagents, methods and apparatus used in the present invention are conventional in the art unless otherwise indicated.
Unless otherwise indicated, reagents and materials used in the present invention are commercially available.
Example 1:
the nutritional food with the function of assisting in reducing blood fat comprises the following components in parts by weight:
350 parts of cured cereal powder (the ratio of the cured oat powder to the cured corn powder is 5: 2),
200 parts of maltodextrin, namely 200 parts of maltodextrin,
150 parts of skimmed milk powder, 150 parts of milk powder,
165 parts of fruit and vegetable powder, namely,
100 parts of trachinotus ovatus blood fat reducing peptide powder,
and 35 parts of sodium carboxymethyl cellulose.
The preparation method of the nutritional food with the function of assisting in reducing blood fat comprises the following steps:
s1 preparation of trachinotus ovatus lipopeptide reducing blood lipid: extracting Trachinotus ovatus meat, adding 1 times of deionized water, mixing, mincing, hydrolyzing with 4000U/g trypsin for 3 hr, inactivating enzyme at 95 deg.C, cooling to 5 deg.C, and centrifuging (separation factor F)rNot less than 800) removing oil and impurities, filtering the clear liquid with 3,000MWCO ultrafiltration membrane, drying the trapped liquid to obtain Trachinotus ovatus blood lipid-reducing peptide powder, wherein the molecular weight distribution of the peptide powder is shown in attached table 1 and attached figure 1, and the proportion of the relative molecular weight of protein hydrolysate is less than 3000Da is more than 95%;
s2, preparing materials: uniformly mixing the raw materials according to the proportion;
s3, packaging: and (6) filling nitrogen and sealing.
The molecular weight distribution of the trachinotus ovatus lipid-lowering peptide powder prepared in the S1 is shown in a figure 1 and a table 1:
table 1: molecular weight distribution of trachinotus ovatus peptide powder obtained before and after ultrafiltration treatment
Example 2
The ratio of cooked cereal powder (cooked oat powder and cooked corn powder is 5: 2) is increased to 500 parts, the ratio of maltodextrin to 50 parts, the ratio of skimmed milk powder to 50 parts, the ratio of trachinotus ovatus to blood fat reducing peptide to 200 parts, and the other components are the same as in example 1.
Example 3
100 parts of cured cereal powder (the ratio of the cured oat powder to the cured corn powder is 5: 2), 500 parts of maltodextrin, 50 parts of skimmed milk powder, 200 parts of trachinotus ovatus blood fat reducing peptide, and the other components are the same as in example 1.
Example 4
The ratio of the cooked cereal powder (cooked oat powder and cooked corn powder is 5: 2) is 50 parts, the ratio of the maltodextrin is 500 parts, and the other components are the same as the components in the example 1.
Example 5
The ratio of the cooked cereal powder (cooked oat powder and cooked corn powder is 5: 2) is 520 parts, the ratio of the maltodextrin is 30 parts, and the other components are the same as the components in the example 1.
Example 6
The weight parts of skimmed milk powder are 220, the weight parts of trachinotus ovatus hypolipemic peptide are 30, and the other components are the same as those in example 1.
Example 7
20 parts of skimmed milk powder, 230 parts of trachinotus ovatus hypolipemic peptide and the same components as in example 1.
Example 8
50 parts of cured cereal powder (the ratio of the cured oat powder to the cured corn powder is 5: 2), 500 parts of maltodextrin, 220 parts of skim milk powder, 30 parts of trachinotus ovatus blood fat reducing peptide powder and the other components in parts by weight are the same as in example 1.
Example 9
500 parts of cooked cereal powder (the ratio of the cooked oat powder to the cooked corn powder is 5: 2), 50 parts of maltodextrin, 20 parts of skimmed milk powder, 230 parts of trachinotus ovatus blood fat reducing peptide powder and the other components in parts as in example 1.
Example 10
In the step S1, the trachinotus ovatus peptide powder is directly dried by ultrafiltration to obtain powder, the molecular weight distribution of the obtained powder is shown in fig. 2 and table 1, and the other component proportions and treatment methods are the same as those in example 1.
The animals tested for reducing blood lipid in examples 1-10 and the positive control cholestyramine were divided into 13 groups of 6 animals each, and the test was repeated three times. The normal control group is fed with basal feed; the hyperlipemia model building group is used for feeding high-fat feed (high-fat feed: 52.2% of basal feed, 20% of cane sugar, 15% of lard, 10% of casein, 1.2% of cholesterol, 0.6% of calcium hydrophosphate, 0.4% of stone powder, 0.4% of premix and 0.2% of sodium cholate); the positive control group was given high-fat diet and gavage cholestyramine (0.2 g/kg. d) daily; high fat diet was administered to each of the groups 1 to 10, and the formula (2.0 g/kg. d) was gavaged each day.
After feeding for 70 days, fasting is carried out for 12h, and orbital blood is taken to separate serum for detecting TC, TG, LDL-C and HDL-C.
3 days before the test is finished, 3 days of test rat feces are collected, freeze-dried and combined to detect the cholesterol content FTC in the feces.
The test results are shown in Table 2 and FIGS. 3 to 7.
The test results show that, compared with the hyperlipidemia animal model group, the examples 1 to 3 can reduce the levels of Total Cholesterol (TC), total triglyceride and low-density lipoprotein cholesterol (LDL-c) in the serum of the experimental rat, improve the level of high-density lipoprotein cholesterol (HDL-c) in the serum and improve the content of cholesterol (FTC) in the feces. Among them, examples 1 and 2 can significantly reduce the levels of TC and LDL-c in rat serum, up-regulate the level of HDL-c, and significantly increase the FTC content in rat feces, showing the effect of promoting cholesterol excretion from the body. Moreover, the experimental data show that the effects of the examples 1 and 2 on reducing serum TC and increasing HDL-c level and FTC level are more obvious than that of the positive control medicament cholestyramine. Further, example 2 is superior to other examples in down-regulating TC, HDL-c and increasing FTC. In examples 7 and 9, due to the slightly high content of the peptide powder of the trachinotus ovatus, although the levels of TG and LDL-c in the serum of rats are higher than those in examples 1 to 3, the effect of reducing TC and FTC in the serum is inferior to that in examples 1 to 3, and the remarkable effect of reducing blood fat cannot be achieved. It can be seen from the experimental data that when the composition ratio of one or both of the cooked cereal powder and the trachinotus ovatus hypolipidemic peptide is lower than a certain range (for example, examples 4, 6 and 8), the effects on TC, TG, LDL-c, HDL-c in the serum of the experimental animal and the effect on fecal FTC are obviously weakened, which shows that there is a certain synergistic effect between the cooked cereal powder and the trachinotus ovatus hypolipidemic peptide. Meanwhile, the content of the cured cereal powder and the lipid-lowering peptide of the trachinotus ovatus have certain upper limits, and as shown in experimental data of examples 5 (excessive cured cereal powder), 7 (excessive cured trachinotus ovatus lipid-lowering peptide) and 9 (excessive cured cereal powder and oval pominotus lipid-lowering peptide), the serum TC level of the rats in the groups is not as reduced as that of examples 2 and 3, and the up-regulation effect on HDL-c in serum and FTC in feces is not as obvious as that of examples 2 and 3. While example 10 using non-ultrafiltrated Trachinotus ovatus peptide powder did not regulate TC, TG, LDL-c, HDL-c and FTC as well as the same amount of Trachinotus ovatus peptide as example 2.
TABLE 2 Effect of intragastric samples on serum blood lipids and fecal blood lipid levels in rats
Note: when the letters marked beside the data are completely different, the difference between groups has statistical significance (p<0.05）。
Claims (4)
1. The nutritional composition for reducing blood fat is characterized by comprising the following components in percentage by mass:
the preparation method of the trachinotus ovatus peptide powder comprises the following steps:
s1, adding 1 time of water into trachinotus ovatus meat and smashing;
s2, adding 2000-6000U/g protease into the crushed trachinotus ovatus in the S1, hydrolyzing for 2-6 hours, inactivating enzyme at 95 ℃, cooling to 4-10 ℃, and centrifuging;
s3, filtering the supernatant obtained after centrifugation in the S2 through a 10,000-3,000 MWCO ultrafiltration membrane, and drying the filtrate to obtain trachinotus ovatus peptide powder;
the content of the cured grain powder in the cured grain powder and the maltodextrin is 60-91%, and the content of the trachinotus ovatus peptide powder in the trachinotus ovatus peptide powder and the skimmed milk powder is 40-80%;
the protein hydrolysate of the trachinotus ovatus peptide powder contains more than 95% of components with relative molecular weight less than 3000 Da.
2. The hypolipidemic nutritional composition of claim 1, wherein the cooked cereal flour is comprised of one or more of cooked oat flour, cooked corn flour, cooked rice flour, cooked black rice flour.
3. The nutritional composition for reducing blood lipid according to claim 1, wherein in S2, the protease is one or more of pepsin, trypsin, alkaline protease and papain; separation factor F in the centrifuger≥800。
4. Use of the hypolipidemic nutritional composition of any one of claims 1 to 3 for the preparation of hypolipidemic drugs, health foods, formulated foods for special medical use or general foods.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610558034.1A CN106173853B (en) | 2016-07-15 | 2016-07-15 | Nutritional composition for reducing blood fat and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610558034.1A CN106173853B (en) | 2016-07-15 | 2016-07-15 | Nutritional composition for reducing blood fat and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106173853A CN106173853A (en) | 2016-12-07 |
| CN106173853B true CN106173853B (en) | 2020-05-19 |
Family
ID=57474501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610558034.1A Active CN106173853B (en) | 2016-07-15 | 2016-07-15 | Nutritional composition for reducing blood fat and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106173853B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109717483B (en) * | 2019-03-15 | 2022-11-15 | 宁波海洋研究院 | Jellyfish peptide formula food with special medical application |
| CN114807276B (en) * | 2022-03-22 | 2024-05-07 | 中国科学院南海海洋研究所 | Egg-shaped pompano hypoglycemic peptide and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589670A (en) * | 2003-08-26 | 2005-03-09 | 中国科学院南海海洋研究所 | Body weight reducing health care product extrated from seaweed and its preparation method |
| CN102077945A (en) * | 2010-09-20 | 2011-06-01 | 王强 | Special dietary seafood for postabortal and postpartum women |
| CN102224899A (en) * | 2011-05-25 | 2011-10-26 | 广州邦世迪生物技术有限公司 | Sugar-free homogenate diet |
| CN103637212A (en) * | 2013-12-13 | 2014-03-19 | 广东省农业科学院蚕业与农产品加工研究所 | Tube feeding clinical nourishment with blood fat reducing effect and preparation method thereof |
| CN104872677A (en) * | 2015-06-18 | 2015-09-02 | 马慧军 | Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof |
| CN105146289A (en) * | 2015-08-21 | 2015-12-16 | 刘涛 | Preparation method of health-care product assisting in lowering blood lipids |
-
2016
- 2016-07-15 CN CN201610558034.1A patent/CN106173853B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1589670A (en) * | 2003-08-26 | 2005-03-09 | 中国科学院南海海洋研究所 | Body weight reducing health care product extrated from seaweed and its preparation method |
| CN102077945A (en) * | 2010-09-20 | 2011-06-01 | 王强 | Special dietary seafood for postabortal and postpartum women |
| CN102224899A (en) * | 2011-05-25 | 2011-10-26 | 广州邦世迪生物技术有限公司 | Sugar-free homogenate diet |
| CN103637212A (en) * | 2013-12-13 | 2014-03-19 | 广东省农业科学院蚕业与农产品加工研究所 | Tube feeding clinical nourishment with blood fat reducing effect and preparation method thereof |
| CN104872677A (en) * | 2015-06-18 | 2015-09-02 | 马慧军 | Dietary composition for benefiting planting and multiplication of probiotics in host body and application thereof |
| CN105146289A (en) * | 2015-08-21 | 2015-12-16 | 刘涛 | Preparation method of health-care product assisting in lowering blood lipids |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106173853A (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11744847B2 (en) | Use of beta-1,3-glucan for modulating immune function and treating intestinal inflammation | |
| WO2007029631A1 (en) | Composition for amelioration of body lipid | |
| CN101715913B (en) | Capsule for regulating blood fat and production process thereof | |
| Shi et al. | The effects of supplementation with blueberry, cyanidin-3-O-β-glucoside, yoghurt and its peptides on obesity and related comorbidities in a diet-induced obese mouse model | |
| WO2006093267A1 (en) | Fermentation composition having immunomodulating effect | |
| CN105747235B (en) | A kind of dietary composition that can improve metabolic syndrome symptom | |
| CN113712205B (en) | Oyster peptide powder composition and preparation method and application thereof | |
| KR20090049604A (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
| JP2018519337A (en) | Method for producing fermented mineral raw pills having a function of improving constipation and fatigue recovery, and fermented mineral raw pills produced thereby | |
| JP4132635B2 (en) | Uninactivated enzyme-enhanced composition | |
| CN106173853B (en) | Nutritional composition for reducing blood fat and application thereof | |
| KR101184349B1 (en) | Composition for enhancement of immune function and improvement of hematopoiesis which comprises antler fermented with Bacillus subtilis KCTC 11454BP as an active ingredient, and a preparation method thereof | |
| Liu et al. | The potential mechanisms of bergamot-derived dietary fiber alleviating high-fat diet-induced hyperlipidemia and obesity in rats | |
| CN111802646A (en) | A nutritional composition for preventing muscle decay and its preparation method | |
| KR101811701B1 (en) | A working method of bran to improve immune function | |
| CN111296755A (en) | A nutrition-enriched oatmeal food containing marine chondroitin sulfate and its preparation method | |
| JP2004097021A (en) | Wakame protein-containing composition, and wakame protein-containing food | |
| JP2001224330A (en) | Food comprising lactobacillus symbiotic culture product and medicinal plant and method for producing the same | |
| Wang et al. | The nutritional value of Spirulina and Utilization Research | |
| JP2002272420A (en) | Antihypertension-relating ingestive material | |
| CN107712875A (en) | Black quinoa weight losing meal-replacing | |
| JP2006298783A (en) | Immunostimulating composition | |
| Laksmitawati et al. | Activity of porang flour and moringa extract to blood glucose and lipid levels in alloxan induced diabetic mice | |
| BR112014032472B1 (en) | PROCESS TO OBTAIN A COMPOSITION UNDERSTANDING BETA-GLICAN, CHITIN AND CHITOSAN, AND RESULTING COMPOSITION OF THE SAME | |
| JP4365012B2 (en) | Method for producing composition for suppressing onset of diabetes and composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |